Literature DB >> 2037667

In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory.

D C Powers1, L F Fries, B R Murphy, B Thumar, M L Clements.   

Abstract

In a double-blind, randomized trial, 102 healthy elderly subjects were inoculated with one of four preparations: (i) intranasal bivalent live attenuated influenza vaccine containing cold-adapted A/Kawasaki/86 (H1N1) and cold-adapted A/Bethesda/85 (H3N2) viruses; (ii) parenteral trivalent inactivated subvirion vaccine containing A/Taiwan/86 (H1N1), A/Leningrad/86 (H3N2), and B/Ann Arbor/86 antigens; (iii) both vaccines; or (iv) placebo. To determine whether local or systemic immunization augmented mucosal immunologic memory, all volunteers were challenged intranasally 12 weeks later with the inactivated virus vaccine. We used a hemagglutination inhibition assay to measure antibodies in sera and a kinetic enzyme-linked immunosorbent assay to measure immunoglobulin G (IgG) and IgA antibodies in sera and nasal washes, respectively. In comparison with the live virus vaccine, the inactivated virus vaccine elicited higher and more frequent rises of serum antibodies, while nasal wash antibody responses were similar. The vaccine combination induced serum and local antibodies slightly more often than the inactivated vaccine alone did. Coadministration of live influenza A virus vaccine did not alter the serum antibody response to the influenza B virus component of the inactivated vaccine. The anamnestic nasal antibody response elicited by intranasal inactivated virus challenge did not differ in the live, inactivated, or combined vaccine groups from that observed in the placebo group not previously immunized. These results suggest that in elderly persons cold-adapted influenza A virus vaccines offer little advantage over inactivated virus vaccines in terms of inducing serum or secretory antibody or local immunological memory. Studies are needed to determine whether both vaccines in combination are more efficacious than inactivated vaccine alone in people in this age group.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037667      PMCID: PMC269808          DOI: 10.1128/jcm.29.3.498-505.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Different protection rates in various groups of volunteers given subunit influenza virus vaccine in 1976.

Authors:  B J Feery; M G Evered; E I Morrison
Journal:  J Infect Dis       Date:  1979-02       Impact factor: 5.226

2.  Effect of influenza vaccines in stimulating antibody in volunteers with prior immunity.

Authors:  D Hobson; F A Baker; R L Curry
Journal:  Lancet       Date:  1973-07-21       Impact factor: 79.321

3.  Influenza subunit vaccine: antibody responses to one and two doses of vaccine and length of response, with particular reference to the elderly.

Authors:  J S MacKenzie
Journal:  Br Med J       Date:  1977-01-22

4.  Impact of epidemic type A influenza in a defined adult population.

Authors:  W H Barker; J P Mullooly
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

5.  Antigenicity of licensed whole virion and subvirion influenza vaccines in "high risk" persons.

Authors:  J A Kasel; R B Couch; H R Six; V Knight
Journal:  Proc Soc Exp Biol Med       Date:  1976-04

6.  Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.

Authors:  J J Treanor; F K Roth; R F Betts
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

7.  Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Authors:  D C Powers; S D Sears; B R Murphy; B Thumar; M L Clements
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

8.  Cold-adapted variants of influenza A virus: evaluation in adult seronegative volunteers of A/Scotland/840/74 and A/Victoria/3/75 cold-adapted recombinants derived from the cold-adapted A/Ann Arbor/6/60 strain.

Authors:  B R Murphy; H P Holley; E J Berquist; M M Levine; S B Spring; H F Maassab; A P Kendal; R M Chanock
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

9.  Influenza vaccination and mortality from bronchopneumonia in the elderly.

Authors:  C H Howells; C K Vesselinova-Jenkins; A D Evans; J James
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

10.  Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers.

Authors:  B R Murphy; M B Rennels; R G Douglas; R F Betts; R B Couch; T R Cate; R M Chanock; A P Kendal; H F Maassab; S Suwanagool; S B Sotman; L A Cisneros; W C Anthony; D R Nalin; M M Levine
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

View more
  15 in total

1.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

Review 2.  Influenza vaccination in the elderly.

Authors:  Jan Smetana; Roman Chlibek; Jana Shaw; Miroslav Splino; Roman Prymula
Journal:  Hum Vaccin Immunother       Date:  2017-08-04       Impact factor: 3.452

Review 3.  Mucosal vaccines for the prevention of influenza.

Authors:  R L Clancy
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

4.  Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers.

Authors:  M L Clements; E K Subbarao; L F Fries; R A Karron; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

5.  Genetically engineered live attenuated influenza A virus vaccine candidates.

Authors:  N T Parkin; P Chiu; K Coelingh
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 6.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

Review 8.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

Review 9.  Vaccine strategies to enhance immune responses in the aged.

Authors:  Julie S Lefebvre; Laura Haynes
Journal:  Curr Opin Immunol       Date:  2013-06-10       Impact factor: 7.486

Review 10.  Cross-protective immune responses elicited by live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik Lin Seong
Journal:  Yonsei Med J       Date:  2013-03-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.